

Press Release 7/2010

Curetis AG: Oliver Schacht elected as member of the Supervisory Board, Anne Burger appointed as CFO.

Curetis completes Supervisory Board and announces new CFO

(Holzgerlingen, July 12, 2010) Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious disease testing, announces the election of Oliver Schacht (Epigenomics AG) as new Supervisory Board Member. In addition, Anne Burger (MedVenture Partners) has been appointed as new CFO.

During the Shareholders' Meeting on June 11, 2010, Oliver Schacht was elected as a member of the Curetis Supervisory Board. Oliver Schacht is a well-known expert in the diagnostics industry with a distinguished career at Epigenomics AG.

Mr. Schacht currently serves as CFO of Epigenomics AG (Berlin, Germany) and CEO for Epigenomics, Inc. (Seattle, USA), and has extensive experience in strategic business development and execution, fundraising (including an IPO), finance, M&A and partnership negotiation. He brings a strong background in the molecular diagnostics industry, with experience ranging from technology development via discovery, clinical validation to market launch of molecular tests.

Mr. Schacht earned a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master's and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting from 1995 to 1998, he worked on projects in M&A, growth strategies and re-organization in pharma, biotech and other sectors.

"We are extremely pleased that Oliver Schacht has agreed to join the Curetis Supervisory Board", said Frank Mühlenbeck, Chairman of the Supervisory Board. "I am sure the company will benefit greatly from his expertise and international business background as it moves toward commercialization of its innovative products."

"I am delighted to have the opportunity to join Curetis Supervisory Board as the company moves ahead," said Oliver Schacht. "I am convinced that Curetis molecular diagnostic tools are unique and destined to become an integral part of routine infectious disease testing. I am particularly excited about the commercial potential of the combination of the Curetis integrated platform with comprehensive content to address high unmet medical needs."

At the same time, Curetis announced the appointment of Anne Burger as CFO, effective immediately.



Curetis AG

Max-Eyth-Straße 42
D-71088 Holzgerlingen

Tel: +49 (0)7031 49195-10
Fax: +49 (0)7031 49195-19

www.curetis.com

Anne Burger is a Director at MedVenture Partners, a Munich-based corporate finance and strategic advisory company focusing on the life sciences and health care industry. At MedVenture Partners, Anne Burger has been responsible for numerous projects in the field of private placements, financial modeling and M&A. She has worked for companies across many segments in biotech, pharma services (CRO), medical devices, medical telemonitoring, hospital service providers and health care IT.

She holds a graduate degree in business administration from the Ludwig-Maximilian-Universität in Munich, with Honors and has completed graduate studies in public health. Mrs. Burger is a regular lecturer at the Odeon Center for Entrepreneurship of the Ludwig-Maximilian-Universität Munich.

Curetis management said “We would like to welcome Anne Burger as the new Curetis CFO. Anne adds important financial skills to the management team. With her more than eight years of experience in financial support for growth stage companies in the life science industry, we are confident that she will make a great contribution to the company’s success.”

About Curetis (Germany)

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective tools for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

Publisher: Curetis AG Dr. Anne Thews, Director Marketing & Sales, Max-Eyth-Straße 42, 71088 Holzgerlingen, Germany, +49 (0) 7031 49195-32, anne.thews@curetis.com, www.curetis.com